Summary:
- The study investigates the role of heparanase, an enzyme that degrades extracellular matrix components, in the progression of pancreatic ductal adenocarcinoma (PDAC).
- Researchers demonstrate that specific heparanase-inhibiting glycans can effectively reduce tumor growth and metastasis by modulating the tumor microenvironment.
- The findings suggest a potential therapeutic strategy for pancreatic cancer by targeting heparanase activity to inhibit disease advancement.